Monobactams are a class of β-lactam antibiotics that contain a single β-lactam ring, unlike penicillins and cephalosporins which have the ring fused to another. Aztreonam was the first to be approved in 1986. Monobactams are effective against gram-negative bacteria and show promise in treating multi-drug resistant pathogens. They work by inhibiting cell wall synthesis through binding to penicillin-binding proteins. Side effects are generally mild but can include rashes, liver problems, and seizures in susceptible individuals.